In the ILLUMINATE trial, within the cohort of persons with diabetes, patients in placebo group were more frequently given add-on insulin [200 patients (5.9%) in placebo and 165 patients (5.04%) in torcetrapib; P = 0.13] and oral antidiabetic therapy [456 patients (13.45%) in placebo and 394 (12.05%); P = 0.09] than in torcetrapib group, potentially suggesting that the true effect of torcetrapib on glucose homeostasis may have been even stronger.23 This evidence concerns the gene INS and diabetes mellitus.